Vaxart (VXRT) Stock Price & Analysis
VXRT Stock Chart & Stats
- Day’s Range
- MXN 12.00 - MXN 12.00
- 52-Week Range
- MXN 12.00 - MXN 12.00
- Previous Close
- MXN 12.00
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- MXN 1.96B
- Enterprise Value
- MXN 95.07M
- Total Cash (Recent Filing)
- MXN 63.98M
- Total Debt (Recent Filing)
- MXN 7.81M
- Price to Earnings (P/E)
- 2.9
- Beta
- 0.17
- Next Earnings
- Nov 05, 2026 (Est.)
- EPS Estimate
- -0.56
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Oral Vaccine Platform
The proprietary oral delivery approach could differentiate Vaxart from injectable competitors through easier administration, storage, and broader deployment potential. Its applicability across COVID, norovirus, influenza, HPV, and HBV also creates a platform opportunity beyond any single vaccine program.
Phase IIb Progress And BARDA Support
Full enrollment advances the company toward a major clinical catalyst while the additional BARDA funding supports deeper genomic, mucosal, and cellular analyses. Together, these developments strengthen program resources and could improve the evidence base for future regulatory or partnering discussions.
Improved Profitability And Cash Generation
The recent shift to positive operating and free cash flow, alongside strong reported margins, improves financial flexibility compared with prior years of losses and cash burn. Conservative leverage further reduces balance-sheet pressure, although the durability of this improvement depends on revenue stability.
Bears Say
Declining And Volatile Revenue
Falling revenue weakens confidence that current profitability and cash generation can persist, particularly because the business has historically shown highly volatile revenue and margins. Continued contraction could reduce internal funding capacity and increase dependence on BARDA, partners, or external capital.
Limited Cash Runway And Funding Risk
The projected runway extends only into Q2 2027, creating a meaningful need to secure partner or non-dilutive funding before major development expenses continue. If those sources are delayed, additional equity financing could dilute shareholders or force slower clinical execution.
Unproven Efficacy And Readout Control
The available clinical evidence supports safety and tolerability but does not yet establish that the oral vaccine improves efficacy outcomes. Similar interim infection counts and BARDA control over future disclosures leave commercialization and partnering decisions dependent on later data with uncertain timing.
Vaxart News
Vaxart reports data from sentinel safety cohort of oral COVID-19 vaccine trial
Vaxart (VXRT) announced topline data from the approximately 400-participant sentinel safety cohort of its Phase 2b clinical trial evaluating the company’s oral pill COVID-19 vaccine candidate against an approved mRNA
VXRT FAQ
What was Vaxart’s price range in the past 12 months?
What is Vaxart’s market cap?
When is Vaxart’s upcoming earnings report date?
How were Vaxart’s earnings last quarter?
Is Vaxart overvalued?
Does Vaxart pay dividends?
What is Vaxart’s EPS estimate?
How many shares outstanding does Vaxart have?
What happened to Vaxart’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Vaxart?
What is the TipRanks Smart Score and how is it calculated?
Vaxart Stock Smart Score
Company Description
Vaxart
Vaxart, Inc. operates as a biotechnology firm currently in the clinical development phase, concentrating its efforts on identifying and advancing novel oral recombinant protein vaccines. The company leverages its unique proprietary platform for delivering these oral vaccine solutions. Its diverse pipeline showcases several promising candidates: An oral tablet vaccine targeting norovirus, which is presently undergoing Phase Ib clinical assessment for both GI.1 and GII.4 strains. A seasonal influenza vaccine, now in Phase II clinical studies, designed to address H1 influenza infections. A vaccine candidate against respiratory syncytial virus (RSV). A coronavirus vaccine, also advancing through Phase II clinical trials for SARS-CoV-2. Beyond infectious diseases, Vaxart is also engaged in formulating therapeutic vaccines aimed at treating cervical cancer and dysplasia associated with human papillomavirus. The company's main operations are situated in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Steven Lo
- Employees
- 65
- Website
- vaxart.com
- Address
- 310 Utah Avenue, South San Francisco, CA, 94080, US
Vaxart (VXRT) Earnings & Revenues
VXRT Earnings Call
Earnings Call SentimentNeutral
The call presents a balanced mix of encouraging clinical and operational developments alongside material financial and timing risks. Key positives include a clean 12‑month safety signal in the sentinel cohort, BARDA’s $29 million contract modification enabling deeper analyses, a fully enrolled ~5,000‑participant main cohort with topline expected H1 2027, governance improvements, and a defined cash runway with flexible financing options. Offsetting these are a ~31.5% year‑over‑year revenue decline, a limited cash runway into Q2 2027 that creates timing pressure for funding or partner opt‑ins, reliance on BARDA for data release timing, uncertainty around the norovirus partnership and development timelines, and that the sentinel cohort was not powered to demonstrate efficacy (symptomatic case counts were similar between arms). On balance, positives (safety readout, BARDA support, large main cohort enrollment, governance actions) are meaningful but are matched by significant near‑term financing and commercialization uncertainties; the overall tone is constructive but cautious.
View all MX:VXRT earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 0 | 12 | 0 |
| Technical Analysis | 0 | 0 | 0 |
| Moving Averages | 0 | 12 | 0 |
